2. Vías de señalización
  3. Metabolic Enzyme/Protease
  4. Aminotransferases (Transaminases)
  5. Aminotransferases (Transaminases) Inhibitor

Aminotransferases (Transaminases) Inhibitor

Aminotransferases (Transaminases) Isoform Comparison

Aminotransferases (Transaminases) Inhibitors (23):

Cat. No. Nombre del producto Efecto Pureza
  • HY-154629
    Sesame Oil
    		Inhibitor 98.2%
    Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities.
  • HY-141669
    BCAT-IN-2
    		Inhibitor 99.07%
    BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC50 of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC50=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.
  • HY-116044
    BCATc Inhibitor 2
    		Inhibitor 99.28%
    BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC50s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively. BCATc, also called BCAT1, is in the cytoplasm.
  • HY-W193545A
    ERG240
    		Inhibitor 98.0%
    ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease.
  • HY-116509
    Linoleylanilide
    		Inhibitor
    Linoleylanilide (Linoleic acid anilide) is a Linoleic acid (HY-N0729) derivative. Linoleylanilide slightly inhibits the PMA (HY-18739)-induced expression of CD11b. Linoleylanilide inhibits serum LDH, GOT and GPT activities. Linoleylanilide decreases red cell counts and hemoglobin content.
  • HY-116451
    PF-04859989 hydrochloride
    		Inhibitor 99.90%
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively).
  • HY-159730
    ERG245
    		Inhibitor 99.49%
    ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC50 of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer.
  • HY-124825
    iGOT1-01
    		Inhibitor 99.18%
    iGOT1-01 is a potent aspartate aminotransferase 1 (glutamate oxaloacetate transaminase 1; GOT1) inhibitor. iGOT1-01 has IC50s of 85 μM and 11.3 μM in MDH coupled GOT1 enzymatic assay and GOT1/GLOX/HRP assay, respectively. iGOT1-01 has anti-cancer activity.
  • HY-141668
    BCAT-IN-1
    		Inhibitor 98.06%
    BCAT-IN-1 is a potent, selective and orally active inhibitor of BCATm, with a pIC50 of 7.3. BCAT-IN-1 shows 100-fold selectivity for BCATm over BCATc (pIC50=5.4). BCAT-IN-1 can be used for the research of metabolic diseases.
  • HY-156962
    BFF-816
    		Inhibitor 99.78%
    BFF-816 is an orally active kynurenine aminotransferase II (KAT II) inhibitor. BFF-816 can be used in the research of the neurobiology of KYNA.
  • HY-W088011B
    Sodium glycolate, 98%
    		Inhibitor 98.0%
    Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt. Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria.
  • HY-169792
    HPG1860
    		Inhibitor 99.9%
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).
  • HY-N6237
    Aspulvinone O
    		Inhibitor
    Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models.
  • HY-169061
    WQQ-345
    		Inhibitor
    WQQ-345 is an orally active BCAT1 inhibitor with an IC50 values of 10.8 mM. WQQ-345 reduces cellular α-KG levels, upregulating H3K27me3 expression, decreasing glycolytic enzyme expression, and impairing glycolysis activity. WQQ-345 reduces colony formation, suppresses growth of BCAT1-high TKI-resistant lung cancer cells. WQQ-345 exerts in vitro and in vivo antitumor activity. WQQ-345 can be used for the research of TKI-resistant non-small cell lung cancer and TKI-resistant lung cancer.
  • HY-168429
    3HKT-IN-1
    		Inhibitor
    3HKT-IN-1 (Compound 17122279) is an Anopheles gambiae 3-hydroxykynurenine transaminase (3HKT) inhibitor. 3HKT-IN-1 can be used for Malaria research.
  • HY-158309
    hOAT-IN-1
    		Inhibitor
    hOAT-IN-1 (compound 5) is a mechanical inhibitor of human ornithine aminotransferase (hOAT). hOAT-IN-1 as a time-dependent inhibitor can form tightly bound PLP inhibitor adduct with hOAT. hOAT-IN-1 can result IN tight occupation of the active site of hOAT. hOAT-IN-1 can be used in the study of lung cell carcinoma .
  • HY-106417
    Limazocic
    		Inhibitor
    Limazocic (SA 3443) is an orally active hepatoprotective agent. Limazocic can inhibit increases in serum transaminase, alkaline phosphatase activity and hepatic lipids, hydroxyproline content induced by CCl4. Limazocic can decrease the degree of hepatic necrosis, fibrosis and steatosis. Limazocic can be used for the research of chronic liver injuries.
  • HY-171035
    PRL-295
    		Inhibitor
    PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen (HY-66005)-induced liver injury in mice.
  • HY-W008440S
    DL-Cycloserine-15N,d3
    		Inhibitor
    DL-Cycloserine-15N,d3 is the deuterium labeled DL-Cycloserine (HY-W008440). DL-Cycloserine is an orally active aminotransferase inhibitor. DL-Cycloserine exhibits completely opposite effects on the activity of monoamine oxidase in different tissues. DL-Cycloserine can be used for the research of pulmonary tuberculosis, psychosomatic diseases, and depressive states.
  • HY-183569
    CSF1R-IN-27
    		Inhibitor
    CSF1R-IN-27 is a CSF1R inhibitor with oral effectiveness, kinome-wide selective profile, low cellular cytotoxicity, and CSF1R IC50 values of 19 nM, 88 nM, 173 nM, 797 nM, 1448 nM, and >3000 nM. CSF1R-IN-27 suppresses M-CSF-induced phosphorylation of CSF1R, AKT, and ERK in macrophages, and inhibits hepatic p-CSF1R/p-AKT/p-ERK signaling. CSF1R-IN-27 reduces serum transaminase levels, improves hepatic histopathology, alleviates inflammatory cell infiltration, and decreases circulating TNF-α and IL-6 levels. CSF1R-IN-27 can be used for the research of acute liver injury.